RxDoctor Payments Data

John Mavropoulos

MOHS-Micrographic Surgery · Orlando, FLNPI 1063737682

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.9% of the total across 109 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,183 and has fallen 76.2% since, to $282 in 2025.

$3,030in general payments, 2019–2025

Across 109 payments — averaging $27.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$687
  • Organogenesis Inc.$421
  • Kerecis Limited$317
  • LEO Pharma Inc.$315
  • Regeneron Healthcare Solutions, Inc.$228
  • Eli Lilly$175
  • plus $887 from 19 others
$9,910in research payments, 2019–2025

Across 2 payments — averaging $4955.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$9K
  • Argenx US, Inc.$1K

What the payments were for

  • Consulting fees$2157%
  • Food & beverage$2,81593%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,030 in reported general payments places this provider in the 65th percentile of 141 mohs-micrographic surgery providers in Florida.

See all mohs-micrographic surgery providers in Florida

Medicare billing

Part B allowed, 2024
$701,992
Medicare patients
422
Services billed
1,715

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Doxycycline Hyclate66$815
Doxycycline Monohydrate27$507

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →